Key result
Two-stage statistical framework classifies hERG safety risk with ≥0.9 AUROC.
Why the study?
A lack of consensus exists on classifying investigational drugs into appropriate risk categories for delayed repolarization and QT interval prolongation based on hERG safety assay results.
A novel two-stage statistical framework for the hERG safety assay accurately classifies investigational drugs for QT prolongation risk with an AUROC ≥ 0.9, offering a standardized approach to address lab-to-lab variability.
The hERG safety assay is crucial for assessing the risk of delayed repolarization and QT interval prolongation in investigational drugs, yet a lack of consensus exists on classifying drugs into appropriate risk categories based on assay results. We propose a two-stage statistical framework for quantitative assessment of hERG safety assay classification for investigational products adhering to ICH E14 S7b Q&A Best Practice protocols. Our framework employs a fixed margin equivalence testing approach to evaluate concurrent positive controls against the positive control reference in Stage 1, followed by a logistic regression model based on a T-score to classify the investigational product into two risk categories (QT effect ≥ 10 msec or < 10 msec) in Stage 2. Applied to real-world data, our method demonstrates the ability to classify investigational products with an AUROC of at least 0.9, using a pre-specified probability margin. Additionally, our approach addresses lab-to-lab variability in hERG safety assay assessment, providing a standardized, quantitative method for evaluating hERG assay results that could improve consistency in drug risk assessment across the pharmaceutical industry.
No takes yet. Share an insight, caveat, or question.
Weng et al. (2026) studied QT interval prolongation risk. Two-stage statistical framework was evaluated on Classification into risk categories (QT effect ≥ 10 msec or < 10 msec) (AUROC ≥0.9). A two-stage statistical framework using fixed margin equivalence testing and logistic regression classified investigational products' hERG safety risk with an AUROC of at least 0.9.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: